Soluble human leukocyte antigen–G serum levels in patients with acquired immune deficiency syndrome affected by different disease-defining conditions before and after antiretroviral treatment

Murdaca, Giuseppe; Contini, Paola; Setti, Maurizio; Cagnati, Paola; Spanò, Francesca; Lantieri, Francesca; Puppo, Francesco

doi:10.1016/j.humimm.2011.05.008

Cited by 6 publications

(8 citation statements)

References 40 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The agents responsible for this increase are nucleoside reverse transcriptase inhibitors rather than protease inhibitors [58]. Murdaca et al explain these conflicting findings in terms of the membrane expression of HLA-G inducing an increase in soluble HLA-G molecule shedding [59]. However, high levels of HLA-G in peripheral monocytes were also observed in two of the 12 untreated patients, suggesting other causes unrelated to HAART [56].…”

Section: Features Of Hla-g Expression By Infection Typementioning

confidence: 99%

Immunomodulatory Properties of HLA-G in Infectious Diseases

Amiot

Samson

2014

Journal of Immunology Research

View full text Add to dashboard Cite

HLA-G is a nonclassical major histocompatibility complex molecule first described at the maternal-fetal interface, on extravillous cytotrophoblasts. Its expression is restricted to some tissues in normal conditions but increases strongly in pathological conditions. The expression of this molecule has been studied in detail in cancers and is now also beginning to be described in infectious diseases. The relevance of studies on HLA-G expression lies in the well known inhibitory effect of this molecule on all cell types involved in innate and adaptive immunity, favoring escape from immune control. In this review, we summarize the features of HLA-G expression by type of infections (i.e, bacterial, viral, or parasitic) detailing the state of knowledge for each pathogenic agent. The polymorphism, the interference of viral proteins with HLA-G intracellular trafficking, and various cytokines have been described to modulate HLA-G expression during infections. We also discuss the cellular source of HLA-G, according to the type of infection and the potential role of HLA-G. New therapeutic approaches based on synthetic HLA-G-derived proteins or antibodies are emerging in mouse models of cancer or transplantation, and these new therapeutic tools may eventually prove useful for the treatment of infectious diseases.

show abstract

Section: Features Of Hla-g Expression By Infection Typementioning

confidence: 99%

Immunomodulatory Properties of HLA-G in Infectious Diseases

Amiot

Samson

2014

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Moreover, sHLA-G levels were significantly higher in AIDS patients before treatment and significantly decreased after antiretroviral therapy. The decrease of sHLA-G was correlated with the decrease of plasma HIV-RNA level and CD8+ T lymphocytes number and with the increase of CD4+ T lymphocytes number [14].…”

Section: Editorialmentioning

confidence: 77%

HLA-G and Virus Infection

2014

J Antivir Antiretrovir

View full text Add to dashboard Cite

“…The observations of Murdaca et al . are very much to this point. This group reported that the serum level of sHLA‐I and sHLA‐G1 and ‐G5 molecules are higher in HIV‐positive subjects than in healthy controls.…”

Section: Discussionmentioning

confidence: 94%

“…Moreover, the peripheral blood mononuclear cells (PBMC) from HIV‐infected individuals spontaneously shed a significantly higher amount of sHLA‐I molecules than peripheral blood mononuclear cells (PBMC) from HIV‐negative subjects. Most importantly, the sHLA‐I level in HIV patients decreased after 36 months of highly active anti‐retroviral therapy, which correlated with the increase in T cell population .…”

Section: Discussionmentioning

confidence: 94%

Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies

Jucaud

Ravindranath

Terasaki

et al. 2015

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Summary T lymphocyte hyperactivity and progressive inflammation in systemic lupus erythematosus (SLE) patients results in over‐expression of human leucocyte antigen (HLA)‐Ib on the surface of lymphocytes. These are shed into the circulation upon inflammation, and may augment production of antibodies promoting pathogenicity of the disease. The objective was to evaluate the association of HLA‐Ib (HLA‐E, HLA‐F and HLA‐G) antibodies to the disease activity of SLE. The immunoglobulin (Ig)G/IgM reactivity to HLA‐Ib and β2m in the sera of 69 German, 29 Mexican female SLE patients and 17 German female controls was measured by multiplex Luminex®‐based flow cytometry. The values were expressed as mean florescence intensity (MFI). Only the German SLE cohort was analysed in relation to the clinical disease activity. In the controls, anti‐HLA‐G IgG predominated over other HLA‐Ib antibodies, whereas SLE patients had a preponderance of anti‐HLA‐F IgG over the other HLA‐Ib antibodies. The disease activity index, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)‐2000, was reflected only in the levels of anti‐HLA‐F IgG. Anti‐HLA‐F IgG with MFI level of 500–1999 was associated with active SLE, whereas inactive SLE revealed higher MFI (>2000). When anti‐HLA‐F IgG were cross‐reactive with other HLA‐Ib alleles, their reactivity was reflected in the levels of anti‐HLA‐E and ‐G IgG. The prevalence of HLA‐F‐monospecific antibodies in SLE patients was also associated with the clinical disease activity. Anti‐HLA‐F IgG is possibly involved in the clearance of HLA‐F shed from lymphocytes and inflamed tissues to lessen the disease's severity, and thus emerges as a beneficial immune biomarker. Therefore, anti‐HLA‐Ib IgG should be considered as a biomarker in standard SLE diagnostics.

show abstract

Soluble human leukocyte antigen–G serum levels in patients with acquired immune deficiency syndrome affected by different disease-defining conditions before and after antiretroviral treatment

Cited by 6 publications

References 40 publications

Immunomodulatory Properties of HLA-G in Infectious Diseases

Immunomodulatory Properties of HLA-G in Infectious Diseases

HLA-G and Virus Infection

Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies

Contact Info

Product

Resources

About